Literature DB >> 18408564

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.

Masahide Fukudo1, Ikuko Yano, Atsushi Yoshimura, Satohiro Masuda, Miwa Uesugi, Keiko Hosohata, Toshiya Katsura, Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Shinji Uemoto, Ken-ichi Inui.   

Abstract

OBJECTIVE: The potential influence of the multidrug resistance 1 (MDR1) gene and the cytochrome P450 (CYP) genes, CYP3A4 and CYP3A5, on the oral clearance (CL/F) of tacrolimus in adult living-donor liver transplant patients was examined. Furthermore, the development of renal dysfunction was analyzed in relation to the CYP3A5 genotype.
METHODS: Sixty de novo adult liver transplant patients receiving tacrolimus were enrolled in this study. The effects of various covariates (including intestinal and hepatic mRNA levels of MDR1 and CYP3A4, measured in each tissue taken at the time of transplantation, and the CYP3A5*3 polymorphism) on CL/F during the first 50 days after surgery were investigated with the nonlinear mixed-effects modeling program.
RESULTS: CL/F increased linearly until postoperative day 14, and thereafter reached a steady state. The initial CL/F immediately after liver transplantation was significantly affected by the intestinal MDR1 mRNA level (P<0.005). Furthermore, patients carrying the CYP3A5*1 allele in the native intestine, but not in the graft liver, showed a 1.47 times higher (95% confidence interval, 1.17-1.77 times, P<0.005) recovery of CL/F with time than patients having the intestinal CYP3A5*3/*3 genotype. The cumulative incidence of renal dysfunction within 1 year after transplantation, evaluated by the Kaplan-Meier method, was significantly associated with the recipient's but not donor's CYP3A5 genotype (*1/*1 and *1/*3 vs. *3/*3: recipient, 17 vs. 46%, P<0.05; donor, 35 vs. 38%, P=0.81).
CONCLUSION: These findings suggest that the CYP3A5*1 genotype as well as the MDR1 mRNA level in enterocytes contributes to interindividual variation in the CL/F of tacrolimus in adult recipients early after living-donor liver transplantation. Furthermore, CYP3A5 in the kidney may play a protective role in the development of tacrolimus-related nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408564     DOI: 10.1097/FPC.0b013e3282f9ac01

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  32 in total

Review 1.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 2.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 3.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

4.  FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.

Authors:  Zhuo Wu; Qinxia Xu; Xiaoyan Qiu; Zheng Jiao; Ming Zhang; Mingkang Zhong
Journal:  Eur J Clin Pharmacol       Date:  2016-10-17       Impact factor: 2.953

Review 5.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

6.  Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.

Authors:  Cécile Gérard; Jeanick Stocco; Anne Hulin; Benoit Blanchet; Céline Verstuyft; François Durand; Filomena Conti; Christophe Duvoux; Michel Tod
Journal:  AAPS J       Date:  2014-02-14       Impact factor: 4.009

7.  Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Authors:  Khaled Benkali; Aurelie Prémaud; Nicolas Picard; Jean-Philippe Rérolle; Olivier Toupance; Guillaume Hoizey; Alain Turcant; Florence Villemain; Yannick Le Meur; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.

Authors:  S Zheng; Y Tasnif; M F Hebert; C L Davis; Y Shitara; J C Calamia; Y S Lin; D D Shen; K E Thummel
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

9.  Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Samer K Khaled; Joycelynne M Palmer; Josef Herzog; Tracey Stiller; Ni-Chun Tsai; David Senitzer; Xueli Liu; Sandra H Thomas; Sepideh Shayani; Jeffrey Weitzel; Stephen J Forman; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-30       Impact factor: 5.742

10.  Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.

Authors:  Sandrine Leroy; Arnaud Isapof; Sonia Fargue; May Fakhoury; Albert Bensman; Georges Deschênes; Evelyne Jacqz-Aigrain; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2010-01-21       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.